scholarly journals Effects of Chinese herbal medicine Pugongying for reducing the application of antibiotics in breastfeeding women with acute mastitis: study protocol of a randomized, active-controlled, outcome assessor-blinded trial

2021 ◽  
Author(s):  
Xinyan Jin ◽  
Chunli Lu ◽  
Jianping Liu ◽  
Yingyi Fan ◽  
Jinhe Xiao ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Health Condition ◽  
Lactating Women ◽  
Outcome Assessor ◽  
Reactive Protein ◽  
Chinese Herbal ◽  
Chinese Patent ◽  
Acute Mastitis

Abstract • Background: Acute mastitis influences the health condition and quality of life of the infants and mothers during the lactation. Pugongying (a kind of Chinese patent medicine, Herba Taraxaci) has shown benefits in lactating women with acute mastitis in clinical practice. However, there is no solid evidence to support its effectiveness and safety.• Methods: A three-arm, multicenter, randomized, active-controlled, outcome assessor-blinded clinical trial will be undergoing in three hospitals in Beijing. 306 participants will be randomly assigned into three groups in 1:1:1 ratio with Pugongying alone, cefdinir alone, and combination of Pugongying and cefdinir for 3-day intervention drugs administration. And in combination of Pugongying and cefdinir group, the participants will be administrated with 2-day cefdinir and 3-day Pugongying. The primary outcomes are resolution of fever, visual analogue scale (VAS) scores of breast pain, and the size of the breast mass by palpation. The secondary outcomes are the patency of milk, Traditional Chinese Medicine (TCM) symptoms scores, white blood cell count, the percentage of neutrophil and C-reactive protein, relapse at 3th day of follow up after completion of treatment, and safety assessment including routine blood, liver and renal function and electrocardiography. Besides, the incidence of surgery and the quantity of additional intervention drugs will also be evaluated.• Discussion: The results of this trial are expected to confirm whether Chinese herbal medicine Pugongying could alleviate the symptoms and signs in lactating women with acute mastitis, and they could reduce application of cefdinir in clinical practice.• Trial registration: ClinicalTrials.gov [Home - ClinicalTrials.gov], ID: NCT03756324. Registered on December 18th 2018. https://www.clinicaltrials.gov/ct2/show/NCT03756324?cond=Acute+mastitis&draw=2&rank=1

scholarly journals Albizia julibrissin Ameliorates Memory Loss Induced by Insomnia in Drosophila

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Jui-Shu Chang ◽  
Hsin-Ping Liu ◽  
Jack Cheng ◽  
Chao-Jung Chen ◽  
Su-Lun Hwang ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Herbal Medicine ◽  
Sleep Deprivation ◽  
Chinese Herbal Medicine ◽  
Cognitive Functions ◽  
Memory Loss ◽  
Short Term ◽  
Albizia Julibrissin ◽  
Chinese Herbal ◽  
Sedative Activity

In clinical practice in Taiwan, Albizia julibrissin is the most prescribed Chinese herbal medicine for insomnia. Short-term insomnia and hypnotic use both attenuate cognitive functions, especially learning memory. In previous studies, A. julibrissin exhibits sedative activity, antidepressant-like effects, and protection of learning and memory against amnesia. However, whether A. julibrissin ameliorates memory loss caused by short-term sleep deprivation is not clear. We utilized the sleep-deprived Drosophila model and olfactory associative learning-memory assay to test the effects of A. julibrissin on sleep-deprivation induced memory loss. We found that A. julibrissin ameliorated 3-hour memory but not 1-hour memory or instant learning. The findings might be applied to an anticipated short-term sleep disturbance.

scholarly journals Clinical practice guidelines and experts’ consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review

2020 ◽  
Author(s):  
Yuxi Li ◽  
Juan Li ◽  
Dongling Zhong ◽  
Yue Zhang ◽  
Yonggang Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Reporting Quality ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal

Abstract Background: The World Health Organization declared on 11 March 2020 that the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has escalated from epidemic into pandemic. As the initial outbreak area, China has taken multiple active measures to deal with the epidemic. Updated versions of diagnosis and treatment guideline for novel coronavirus (COVID-19) patients have been issued, and traditional Chinese herbal medicine has been recommended as a treatment. The objective of this study will be to summarize the recommendations in current clinical practice guidelines about the use of traditional Chinese herbal medicine for COVID-19 patients. We will also evaluate and report on the methodological and reporting quality of these guidelines.Methods: In this systematic review, we will search for guidelines, expert consensuses and policy documents published since December 2019 in electronic databases (e.g. PubMed, EMBASE, and Chinese databases) and on websites of governments or organizations (e.g. The National Guideline Clearinghouse [NGC], Guidelines International Network [GIN], National Institute for Health and Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network [SIGN] and WHO]). Eligible documents will be independently selected, and relevant data will be independently extracted by two reviewers. We will also independently evaluate the methodological quality and reporting quality of the included guidelines, using the Appraisal of Guidelines for REsearch & Evaluation (AGREE) II tool and Reporting Items for Practice Guidelines in healthcare (RIGHT) statement, respectively. Any discrepancies will be discussed and resolved through discussion among the reviewers. We will use the extracted information to summarize their recommendations for traditional Chinese herbal formulae and Chinese patent medicine for COVID-19 patients, and to summarize the strength and quality of these recommendations with reference to the results of AGREE II and RIGHT tools.Discussion: This review will summarize the recommendations in current clinical practice guidelines and provide insight into the implementation strategies for traditional Chinese herbal medicine in COVID-19 patients. Systematic review registration: PROSPERO registration number: CRD42020179205

scholarly journals The characteristics and prescription patterns of Chinese herbal medicine in clinical practice for the treatment of anemia

2018 ◽  
Vol 57 (4) ◽  
pp. 570-577 ◽  
Author(s):  
Wei-Di Chen ◽  
Hung-Sen Huang ◽  
Yuan-Chih Su ◽  
Shen-Chieh Chou ◽  
Wen-Chao Ho ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Prescription Patterns ◽  
Chinese Herbal

scholarly journals Treating COVID-19 with Chinese Medicine in UK

2021 ◽  
pp. 1-4
Author(s):  
Shulan Tang ◽  
Keyword(s):  
Clinical Practice ◽  
Chinese Medicine ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Mild Case ◽  
Treatment Principles ◽  
Chinese Herbal ◽  
Stress Syndrome ◽  
Liver And Kidney ◽  
Related Stress

The author has been using Chinese herbal medicine to treat people via video call consultations through the pandemic, with good success. She has carefully observed, analysed, classified and summarized the symptoms. She had highlighted that the covid virus does not only affect the function of the lung, but also affects the function of the spleen, heat, liver and Kidney. She has mainly seen the following four types of disease: Suspected Covid-19, Covid-19 mild case, Post virus syndromes and Covid-19 related stress syndrome. She has created treatment principles and selected suitable prescriptions for each Zhuang Fu system, according to the different symptoms and differentiations; giving great guidance to clinical practice and study

scholarly journals Clinical Practice Guidelines of Traditional Chinese Herbal Medicine for Novel Coronavirus (Covid-19): Protocol of a Systematic Review

2020 ◽  
Author(s):  
Yuxi Li ◽  
Juan Li ◽  
Dongling Zhong ◽  
Yue Zhang ◽  
Yonggang Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Practice ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Practice Guidelines ◽  
Agree Ii ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Novel Coronavirus

Abstract Background: The World Health Organization declared on 11 March 2020 that thespread of the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) had escalated from epidemic into pandemic. As the initial outbreak area, China has taken multiple active measures to deal with the epidemic. Updated versions of diagnosis and treatment guideline for novel coronavirus (COVID-19)patients have been issued, and traditional Chinese herbal medicine has been recommended as a treatment.Methods: In this systematic review, we will search for guidelines, expert consensuses and policy documents published since December 2019 in electronic databases and on websites of governments or organizations. Eligible documents will be independently selected, and relevant data will be independently extracted by two reviewers. We will also independently evaluate the methodological quality and reporting quality of the included guidelines, using the Appraisal of Guidelines for REsearch& Evaluation (AGREE) II tool and Reporting Items for Practice Guidelines in healthcare (RIGHT) statement, respectively. Any discrepancies will be discussed and resolved through discussion among the reviewers. We will use the extracted information to summarize their recommendationsfor traditional Chinese herbal formulae and Chinese patent medicine for COVID-19 patients, and to summarize the strength and quality of these recommendations with reference to the findings from the AGREE II and RIGHT tools.Discussion: This review will summarize the recommendations in current clinical practice guidelines andprovide insight into the implementation strategies for traditional Chinese herbal medicine in COVID-19 patients. Systematic review registration: PROSPERO registration number: CRD42020179205

The effect of the chinese herbal medicine Dai-Kenchu-To on intestinal blood flow

2001 ◽  
Vol 120 (5) ◽  
pp. A248-A248
Author(s):  
N KAWASAKI ◽  
K NARIAI ◽  
M NAKAO ◽  
K NAKADA ◽  
N HANYUU ◽  
...  
Keyword(s):  
Blood Flow ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Intestinal Blood Flow ◽  
Chinese Herbal
Sign in / Sign up

Export Citation Format

Share Document